Key Points
- Royalty Pharma EVP George Lloyd sold 30,654 shares on Dec. 18 at an average price of $38.50, totaling $1,180,179, a transaction disclosed in an SEC Form 4.
- The company posted quarterly EPS of $1.17 (beating $1.11) but revenue of $609.3M missed the $765M estimate; RPRX trades around $38.60, has a $22.28B market cap, pays a $0.22 quarterly dividend (2.3% yield), and carries a consensus "Moderate Buy" rating with an average price target of $45.60.
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP George Lloyd sold 30,654 shares of the firm's stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $38.50, for a total value of $1,180,179.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Royalty Pharma Stock Up 0.4%
RPRX opened at $38.60 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The company has a market cap of $22.28 billion, a price-to-earnings ratio of 29.24, a PEG ratio of 2.02 and a beta of 0.47. Royalty Pharma PLC has a one year low of $24.32 and a one year high of $41.24. The business's fifty day moving average is $38.36 and its two-hundred day moving average is $36.74.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.
Royalty Pharma Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th were given a dividend of $0.22 per share. The ex-dividend date was Friday, November 14th. This represents a $0.88 dividend on an annualized basis and a yield of 2.3%. Royalty Pharma's payout ratio is presently 66.67%.
Analyst Ratings Changes
A number of research analysts have recently weighed in on RPRX shares. TD Cowen raised their price objective on shares of Royalty Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, December 11th. Cowen restated a "buy" rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Morgan Stanley dropped their price objective on Royalty Pharma from $55.00 to $54.00 and set an "overweight" rating for the company in a research report on Friday, October 10th. Wall Street Zen lowered shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a report on Friday, November 28th. Finally, Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a report on Thursday, December 11th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $45.60.
Check Out Our Latest Analysis on Royalty Pharma
Institutional Trading of Royalty Pharma
A number of hedge funds have recently added to or reduced their stakes in RPRX. Smartleaf Asset Management LLC increased its stake in shares of Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 790 shares during the last quarter. USA Financial Formulas acquired a new position in Royalty Pharma during the second quarter worth approximately $32,000. Financial Consulate Inc. acquired a new position in shares of Royalty Pharma in the 3rd quarter valued at $35,000. WPG Advisers LLC purchased a new stake in shares of Royalty Pharma during the 1st quarter valued at $39,000. Finally, Larson Financial Group LLC grew its stake in shares of Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 306 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
